-
NEWS RELEASE
April 19, 2024 is World Liver Day!
2024.04.19
As part of our efforts to raise awareness about liver health and the prevalence of liver disease around the world, we raise our voices on this important day as well.
-
UPCOMING EVENTS
SMC will be exhibiting at The 110th General Meeting of the Japanese Society of Gastroenterology
2024.04.11
We are pleased to announce that SMC Laboratories will be exhibiting at The 110th General Meeting of the Japanese Society of Gastroenterology from May 9th (Thu) to 11th (Sat).
-
NEWS RELEASE
【The path to next-generation MASH therapeutics】 FDA-approved Resmetirom and the possibilities beyond
2024.03.29
If you are developing a MASH drug, it might be beneficial to develop a drug for a different target than Rezdiffra (resmetirom), developed by Madrigal Pharmaceuticals, as the first treatment for MASH, to treat more MASH patients.
-
PRODUCTS AND SERVICES
【Hot data】 Resmetirom (MGL-3196) evaluation data available in STAM model
2024.03.26
As you may already know, the United States Food and Drug Administration (FDA) announced the approval of Rezdiffra (resmetirom), developed by Madrigal Pharmaceuticals, as the first treatment for MASH.
-
NEWS RELEASE
【Breaking News!】 First MASH treatment approved by FDA
2024.03.22
On March 14th, The United States Food and Drug Administration (FDA) announced their approval of Rezdiffra (resmetirom), developed by Madrigal Pharmaceuticals, as the first treatment for MASH.
-
PRODUCTS AND SERVICES
2024.03.14
If you are considering a drug evaluation study for liver cancer using a mouse model, our STAM™-HCC/IO⁺ model best replicates the pathology and characteristics seen in human patients with liver cancer, which allows for the optimal evaluation of your compound's efficacy.
-
PRODUCTS AND SERVICES
The [optimal disease model] that maximizes your research outputs.
2024.03.12
The bleomycin-induced pulmonary fibrosis mouse model is commonly used to replicate the pathogenesis of IPF in humans. If you are considering using a mouse model of pulmonary fibrosis for drug evaluation studies, then using a suitable study design allows you to best evaluate the efficacy of your compound.
-
PRODUCTS AND SERVICES
【Case Study】Why do disease model mice change the outcomes?
2024.03.08
If you are considering using a lung fibrosis model in a drug efficacy study, you can maximize the efficacy of your compound by using a disease induction model that is appropriate for your evaluation, rather than using a standard pathological model.
-
PRODUCTS AND SERVICES
Introduction of [Pathway MAP of MASH compounds] to accelerate your research
2024.03.05
When conducting non-clinical research, it is important to choose an appropriate mouse model that reproduces human pathology and also allows your compound to be evaluated.
-
PRODUCTS AND SERVICES
Preclinical COPD study with positive controls, Roflumilast
2024.02.29
Today, we share an update regarding new preclinical service.
-
PRODUCTS AND SERVICES
Introduction of Chronic Kidney Disease Mice Models
2024.02.22
I am writing you today to share some information on our chronic kidney disease (CKD) models.
-
NEWS RELEASE
Cholangiocarcinoma and Primary sclerosing cholangitis
2024.02.15
On February 15, World Cholangiocarcinoma Day!